These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 26341360

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN, Meijers JC.
    J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F, Carrieri C, Semeraro N, Colucci M.
    Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor.
    Buelens K, Hassanzadeh-Ghassabeh G, Muyldermans S, Gils A, Declerck PJ.
    J Thromb Haemost; 2010 Jun; 8(6):1302-12. PubMed ID: 20180900
    [Abstract] [Full Text] [Related]

  • 30. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL.
    J Biol Chem; 2003 Dec 19; 278(51):51059-67. PubMed ID: 14525995
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.
    Schneider M, Nagashima M, Knappe S, Zhao L, Morser J, Nesheim M.
    J Biol Chem; 2002 Mar 22; 277(12):9944-51. PubMed ID: 11786552
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
    Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L.
    Thromb Haemost; 1997 Jul 22; 78(1):386-91. PubMed ID: 9198184
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.
    Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.
    J Thromb Haemost; 2017 Nov 22; 15(11):2218-2225. PubMed ID: 28834317
    [Abstract] [Full Text] [Related]

  • 40. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C, Stafford AR, Fredenburgh JC, Weitz JI, Gils A, Declerck PJ, Kim PY.
    Thromb Haemost; 2017 Jul 26; 117(8):1509-1517. PubMed ID: 28640323
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.